Welcome to our dedicated page for Relmada Therapeutics news (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics stock.
Relmada Therapeutics, Inc. develops clinical-stage therapies for oncology and central nervous system disorders. Company news centers on NDV-01, an intravesical sustained-release gemcitabine-docetaxel therapy being evaluated for non-muscle invasive bladder cancer, including clinical data, FDA feedback on registrational study design, and presentations at medical conferences.
Recurring updates also cover quarterly and annual financial results, business progress, healthcare conference participation, and financing activity tied to the company’s clinical development plans.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced that CEO Sergio Traversa will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on February 25, 2021, at 3:40 p.m. ET. The event will be webcast live, with a replay available for 90 days. Relmada focuses on addressing central nervous system diseases, particularly major depressive disorder (MDD), with its lead program, REL-1017, in late-stage development as an adjunctive treatment for MDD in adults. The press release includes forward-looking statements regarding risks and uncertainties.
Relmada Therapeutics (Nasdaq: RLMD) announced the enrollment of the first patient in its Phase 3 trial (RELIANCE I) for REL-1017 as an adjunctive treatment for major depressive disorder (MDD). CEO Sergio Traversa highlighted this as a significant milestone, emphasizing guidance from the FDA based on positive Phase 2 results. The Phase 3 program features two trials involving 400 MDD patients across 55 sites in the U.S. Key endpoints include assessing changes in depression scores at day 28, with top-line results expected in the first half of 2022.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) will have its CEO, Sergio Traversa, participate in two virtual investor conferences. The first is the Jefferies London Healthcare Conference on November 19, 2020, at 10:50 AM EST, with a live webcast available on their website. The second is the Piper Sandler 32nd Annual Healthcare Conference, where a fireside chat will be accessible starting November 23, 2020. Relmada specializes in therapies for CNS diseases, focusing on major depressive disorder (MDD) with its lead program REL-1017.
Relmada Therapeutics (Nasdaq: RLMD) has expanded its leadership with the appointments of Paolo Manfredi, M.D., as Acting Chief Scientific Officer and Marco Pappagallo, M.D., as Acting Chief Medical Officer. Both bring extensive experience in CNS therapies. The company is on track to start its pivotal Phase III trial of REL-1017 for major depressive disorder (MDD) by Q4 2020, along with other significant milestones planned for 2021, including human abuse potential studies and additional trials. REL-1017 has demonstrated promising results in previous studies.
Relmada Therapeutics (Nasdaq: RLMD) received a Notice of Allowance from the Canadian Intellectual Property Office for its patent on REL-1017, a novel NMDA receptor antagonist. This patent broadens its intellectual property in Canada, a key market for treating psychological disorders such as depression and anxiety. The company is set to initiate its Phase 3 program for REL-1017 in Q4 2020 after receiving FDA clearance to proceed without further trials. REL-1017 showed promising Phase 2 results, demonstrating significant antidepressant effects and a favorable safety profile.